Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 13/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.33 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.33 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092424 | 0.90 | KDM5A (0.42) | KDM5AXDH | |
| SCHEMBL17547807 | 0.89 | KDM5A (0.38) | KDM5AKDM5CKDM4CKDM5BKDM6B | |
| SCHEMBL17547833 | 0.86 | KDM5A (0.39) | KDM5AKDM5CKDM4CKDM5B | |
| SCHEMBL16092329 | 0.86 | KDM5A (0.55) | KDM5AKDM5CKDM4CKDM5BKDM6B | |
| SCHEMBL17547826 | 0.85 | KDM5A (0.39) | KDM5AKDM5CKDM4CKDM5BKDM6B | |
| SCHEMBL17547805 | 0.85 | KDM5A (0.39) | KDM5AKDM5CKDM4CKDM5BKDM6B | |
| SCHEMBL16092315 | 0.84 | KDM5A (0.57) | KDM5AXDHKDM5CKDM4CKDM5B | |
| SCHEMBL16092521 | 0.84 | KDM5A (0.39) | KDM5AKDM5CKDM4CKDM5B | |
| SCHEMBL16092525 | 0.84 | KDM5A (0.40) | KDM5AXDH | |
| SCHEMBL16092328 | 0.83 | KDM5A (0.39) | KDM5AKDM5CKDM4CKDM5BKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | KDM5A 1/4885XDH 238/4885SCN5A 472/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | KDM5A 1/4885XDH 238/4885SCN5A 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.